Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SMO | Q99835 | 4/20 | 0.32 |
| ▸ | ME2 | P23368 | 4/20 | 0.32 |
| ▸ | ME1 | P48163 | 4/20 | 0.32 |
| ▸ | ME3 | Q16798 | 4/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 4/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.31 |
| ▸ | KDM4A | O75164 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3320866 | 0.78 | L3MBTL1 (0.32) | SCN9AL3MBTL1 | |
| SCHEMBL3320069 | 0.77 | KMT2A (0.50) | NAMPT | |
| SCHEMBL3319297 | 0.77 | L3MBTL1 (0.62) | L3MBTL1SMODPP4DPP9 | |
| SCHEMBL3320722 | 0.77 | DPP4 (0.49) | DPP4DPP9 | |
| SCHEMBL3319624 | 0.76 | HTR2A (0.50) | L3MBTL1NAMPT | |
| SCHEMBL3319737 | 0.75 | HTT (0.43) | NAMPTBLM | |
| SCHEMBL3320848 | 0.73 | HPGD (0.44) | — | |
| SCHEMBL3321806 | 0.70 | POLB (0.45) | L3MBTL1ME2ME1ME3 | |
| SCHEMBL3322025 | 0.69 | CHRNA4 (0.43) | NAMPT | |
| SCHEMBL3317732 | 0.69 | SIGLEC9 (0.43) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100125075-A1 | Antibacterial Agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2010-05-20 | — | — | US | disclosed |
| US-7186719-B2 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS (GB) | 2007-03-06 | — | — | US | disclosed |
| US-20050065095-A1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2005-03-24 | — | — | US | disclosed |
| US-6846825-B1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2005-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065095-A1 | Antibacterial agents | NQO2, DAO, Q6ZSR9 | SCN9A 1939/4885L3MBTL1 2349/4885SMO 4732/4885 |
| US-20100125075-A1 | Antibacterial Agents | NQO2, DAO, Q6ZSR9 | SCN9A 2076/4885L3MBTL1 1972/4885SMO 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.